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Objectives. Esophageal carcinoma and cirrhosis have the overlapping etiologic factors. Methods. In a retrospective analysis
conducted in 2 Breton institutions we wanted to asses the frequency of this association and the outcome of these patients in a
case-control study where each case (cirrhosis and esophageal cancer) was paired with two controls (esophageal cancer). Results.I n
a 10-year period, we have treated 958 esophageal cancer patients; 26 (2.7%) had a cirrhosis. The same treatments were proposed to
the 2 groups; cases received nonsigniﬁcantly diﬀerent radiation and chemotherapy dose than controls. Severe toxicities and deaths
were more frequent among the cases. At the end of the treatment 58% of the cases and 67% of the controls were in complete
remission; median and 2-year survival were not diﬀerent between the 2 groups. All 4 Child-Pugh B class patients experienced
severe side eﬀects and 2 died during the treatment. Conclusions. This association is surprisingly infrequent in our population!
Child-Pugh B patients had a dismal prognosis and a bad tolerance to radiochemotherapy; Child-Pugh A patients have the same
tolerance and the same prognosis as controls and the evidence of a well-compensated cirrhosis has not modiﬁed our medical
options.
Copyright © 2009 Florence Trivin et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The incidence of oesophageal cancer is high in France and
particularly in Brittany [1]. Alcohol and smoking are the
main etiological factors of squamous-cell carcinoma [2], the
most frequent type of oesophageal cancer in our region.
This alcohol-smoking combination also predisposes to cir-
rhosis, with alcoholic cirrhosis being frequent and smoking
increasing the severity of liver diseases [3]. The possible
association of oesophageal cancer and cirrhosis worsens the
prognosis and raises serious therapeutic problems. Surgery
is often contraindicated or associated with a high morbidity
[4, 5], but to our knowledge, no data are currently available
concerning whether these patients could beneﬁt from a
speciﬁc medical treatment. It is also unknown whether
their prognosis is diﬀerent from patients with cancer of the
oesophagus but without cirrhosis. We therefore analyzed
retrospectively the frequency of this association in our
patient population in order to examine treatment eﬃcacy
and develop a therapeutic proposal.
2.MaterialsandMethods
This retrospective study included all patients treated for
cancer of the oesophagus between January 1, 1993 and
December 31, 2002 at two cancer centers in Brittany, the
Centre Eug` ene-Marquis (CEM) (the regional comprehensive
cancer center located in the city of Rennes) and the Centre
Hospitalier de Bretagne Sud (CHBS) (located in the city
of Lorient). We retained for analysis all patients with the
diagnosis of both cancer of the oesophagus and cirrhosis.
Medical ﬁles were re-examined to conﬁrm the diagnosis
of associated cirrhosis. Each patient in this group (case
group) was matched with two patients with cancer of the
oesophagus but without cirrhosis (control group) treated at
the CEM during the same period. Patients were matched2 Journal of Oncology
for gender, age (±5 years), TNM stage, tumor localization
(upper, middle, lower oesophagus), histological type, and
period of treatment (±2y e a r s ) .
The following data were noted for each patient: gender,
age, alcohol-tobacco consumption, histology, tumor local-
ization, TNM stage (assessed with computed tomography
or endoscopic ultrasonography), type of treatment (surgery,
radiotherapy-chemotherapy, chemotherapy, other), radia-
tion dose, total chemotherapy dose administered (expressed
in percent of theoretical dose per body surface area),
treatment adaptations, toxicity (CTC-NCI classiﬁcation,
version 2.0), tumor stage at treatment end, recurrence
and date of death or last follow-up; information, etiology,
circumstanceofdiscovery,Child-Pughscore,inpatientswith
cirrhosis.
Quantitative variables (survival, radiotherapy dose) were
e x p r e s s e da sm e d i a no rm e a n± standard deviation (SD).
Qualitative variables were expressed as number (n)a n d
percentage (%). Overall survival was determined from the
date of diagnosis to the date of death or last follow-up
information. For patients who achieved complete remission,
recurrence-free survival was determined from diagnosis to
date of progression or last follow-up information. Complete
remission was deﬁned as absence of suspected oesophageal
lesions at endoscopy, normal histology of systematic biopsy
specimens, and absence of tumor aspect on the computed
tomography (CT) performed approximately three months
after the end of the radiation protocol. Survival curves were
established using the Kaplan-Meier method and compared
with the log-rank test. P<. 05 was considered signiﬁcant.
The chi-square test with Yates correction as appropriate was
applied to compare qualitative variables.
3. Results
From January 1, 1993 to December 31, 2002, 671 and 287
patients were treated for oesophageal cancer at the CEM
and CHRBS, respectively. For 26 of these 958 patients (3%),
the summary diagnosis mentioned “cirrhosis.” The tumor
staging in these 26 patients (21 men, 5 women, mean age
58.9 ± 7.7 years) was IIA (n = 4), IIB (n = 3), III (n =
18), IV (n = 1). All 26 had alcoholic cirrhosis which was
known before the diagnosis of oesophageal cancer in 11
(38.5%). Histological proof of cirrhosis was available for
seven patients. The diagnosis was based on the presence
of oesophageal varices (often associated with a history of
hepatic decompensation with edema and ascites) in sixteen
patients and on a previous history of decompensation with
edemaandascitesinthree.TheChild-Pughclassiﬁcationwas
A in 22 and B in 4. Among these 4 Child B patients none had
ascites.
3.1. Treatments Administered and Toxicity in the Case Group.
Among the 26 patients in the case group, none had been
operated, 25 were given combined radiochemotherapy using
the Herskovic protocol [6] in 16 and another protocol in 9;
in these 9 cases the chemotherapy protocol also used 5FU
and CDDP following an LV5FU2 regimen associated with
CDDP at the dose of 50mg/m2 every two weeks. One patient
with metastatic disease was given chemotherapy (5FU and
CDDP) alone. Compared with the theoretical dose for the
prescribed Herskovic protocol, the dose delivered was 75 ±
25% for CDDP and 59 ± 32% for 5FU (partly because the
5FU dose was decreased to 600mg/m2 from the ﬁrst session
for 14 patients). Median radiation dose delivered was 54 Gy
(range 12–65 Gy). Haematologic and digestive toxic eﬀects
are summarized in Table 1. Other severe complications were
noted in 9 patients (35%): hepatic decompensation in 5
(leading to death in 2), acute lower limb ischemia following
chemotherapy infusion in 1 patient, hepatic encephalopathy
in 1 patient (death), hematemesis in 1 patient (death),
hemoperitoneum subsequent to gastric invasion in 1 patient
(death). In all, 5 patients died during treatment; four deaths
(15.5%) were related to cirrhosis. Chemotherapy delivery
had to be modiﬁed because of toxic eﬀects in 9 patients
(34.5%).
At the end of treatment, 5 patients (19%) including
two classiﬁed Child B had died, 15 patients (58%) were in
complete remission, and 6 (23%) had active disease. Median
survival was 10 months (range 1–61 months). Overall 2-
year survival was 28 ± 9%. Median recurrence-free survival
was 13 months; the 2-year recurrence-free survival rate was
42 ± 14%.
3.2. Comparison with the Control Group. The matched
control group showed no signiﬁcant diﬀerence from the
case group but there were fewer (NS) alcoholic patients
in the control group. There was no signiﬁcant diﬀerence
between the groups for choice of treatment: 44 of the 52
control patients were given combined radiochemotherapy
(with a Herskovic protocol for 28 and an LV5FU2-CDDP
ergimen for the others) and 4 were given chemotherapy
alone, but 4 patients in the control group underwent
surgery. The radiation dose delivered was 50 Gy (range
30–65 Gy) and the percentage of the theoretical dose was
73 ± 25% for CDDP and 67 ± 25% for 5FU. This was
not signiﬁcantly diﬀerent from the case group. Regarding
the classical toxic eﬀects of chemotherapy (Table 1), there
were more cases of grade 3-4 mucitis in the control group
(16/48 versus 2/26 in the case group, P = .05). There was
not however any signiﬁcant diﬀerence for hematological,
gastrointestinal, or renal complications. Nine patients (16%)
in the control group presented other severe complications:
major degradation of general status in 1, severe pneumonia
in 3, septic shock in 2, abdominal wall infection on
a jejunostomy oriﬁce in 1, rhythm disorder in 1, and
esophagotracheal ﬁstulization leading to death in 3 patients
(6%).Surprisingly,theproportionofpatientswhodeveloped
severe grade 3-4 or fatal complications was not signiﬁcantly
diﬀerent between the two groups (Table 1): 11/26 in the
case group and 21/48 in the control group. There were
fewer deaths in the control group (n = 3, 6% versus
n = 5, 19% in the case group) but the diﬀerence was
not signiﬁcant.
In the control group, at the end of treatment 3 patients
had died, 35 (67%) were in complete remission, and 14 had
active disease. There was no signiﬁcant diﬀerence (P = .18)
in terms of outcome after treatment between the two groups.Journal of Oncology 3
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Figure 1:Overallsurvivalinthecontrolgroup(esophagealcancers)
and in the case group (esophageal cancer in cirrhotic patients): no
signiﬁcant diﬀerence between the two groups.
Overall survival was not signiﬁcantly diﬀerent between
the two groups (Figure 1). Median survival was 10 months
in the case group and 14 months in the control group. The
overall 2-year survival rate was 38 ±9% in the control group
versus 28 ±9% in the case group (NS).
There was no signiﬁcant diﬀerence in recurrence-free
survival between the two groups. Median recurrence-free
survival was 14 months in the control group and the 2-
year recurrence-free survival rate was 37 ±7% in the control
group.
3.3. Comparison by Child-Pugh Score. Despite the small
number of Child B patients, there was a marked diﬀerence
in survival between Child A and Child B patients (P =
.04) (Figure 2). The 1-year survival was 67% for Child A
patients and 0% for Child B patients. This diﬀerence in
prognosis was not related to age or major diﬀerence in
tumor severity. There was however a diﬀerence in terms
of treatment tolerance. Tolerance was poorer in Child B
patients, all treated with combined radiochemotherapy. All
developed a major complication: death due to liver failure
with edema and ascites, death with hemiperitoneum, grade 4
thrombopenia, grade 4 neutropenia. The 4 Child B patients
died within one year of diagnosis, two during treatment,
one at six months from disease progression, and one at 10
months from an unknown cause despite complete remission.
4. Discussion
This small series of patients highlights several interesting
points. The frequency of cirrhosis was surprisingly low
among our patients with cancer of the oesophagus. The
treatments proposed were very similar for patients with and
without cirrhosis, although surgery was never proposed for
cirrhotic patients. Toxic eﬀects were particularly severe in
cirrhotic patients but were generally related to their liver
disease; there was no diﬀerence in the rate of “classical” com-
plications, particularly hematological disorders or mucitis,
which was less frequent in cirrhosis patients despite similar
treatments (radiation dose and chemotherapy). Treatment
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Figure 2: Overall survival in the cirrhotic patients with esophageal
carcinoma: signiﬁcant diﬀerence between class A and class B
patients.
Table 1: Chemotherapy toxicity (grade 3/grade 4) in oesophageal
cancer patients with (case group) or without liver cirrhosis (control
group);severetoxicitycorrespondstopatientwithatleastonegrade
3o r4t o x i c i t y .
Case group
n = 26
Control group
n = 48 P
Platelets grade 3/4 2/1 4/1 NS
PMN grade 3/4 5/2 4/4 NS
Mucitis grade 3/4 2/0 12/4 .05
Vomiting grade 3/4 2/0 0/0 NS
Other: severe 9 9 NS
Death during
treatment 53 N S
Severe toxicity:
no/yes 11/15 21/27 NS
eﬃcacy and survival were not diﬀerent between the groups.
Toxicity was however a major problem in Child B patients
whose prognosis was much less favorable.
In our case population, the proportion of cirrhotic
patients (3%) was much lower than generally reported. Two
studies from Japan [5]a n dI t a l y[ 7] have reported the
cirrhosis-oesophageal cancer association in 7% and 14% of
patients. In a French autopsy report [8], liver disease (alco-
holic cirrhosis, acutealcoholichepatitis, hepatic ﬁbrosis) was
found in 18% of patients who had died from oesophageal
cancer. There could be several explanations for this apparent
discrepancy.First,gastroenterologists,whoreferredallofour
patients, probably preferentially selected cirrhotic patients
for endoscopic treatment or therapeutic abstention. This
could certainly explain the absence of Child C patients.
Esophagogastroduodenal endoscopy was performed in all
patients, enabling detection of oesophageal varices if the
scope could be passed through the stricture. Prothrombin
time and other laboratory tests were also available for all
patients, but no attempt was made to systematically search
for purely histological forms of cirrhosis. This probably led
to a clinical underestimation of cirrhosis in comparison4 Journal of Oncology
with surgical series where there is at least a macroscopic
assessment of liver disease. Age at disease onset, as well as
favoring factors, is similar for the two conditions under con-
sideration [9]. Certain protective factors (diﬀerent metabolic
mechanism of carcinogenesis in the presence of cirrhosis?),
or on the contrary, phenotypic or genotypic conﬁgurations
possibly aggravating toxic eﬀects could also be involved. A
recent report from China demonstrated diﬀerences in the
frequency of ADH2 and ALDH2 genes between alcoholic
patients who developed alcoholic cirrhosis and those who
developed oesophageal cancer [10] but no similar data are
currently available for French patients. One other Breton
team [11] has examined the genetic polymorphism of two
P450 cytochromes (CYP2EI and CYP1A1) among alcoholic
patients with diverse complications (including cirrhosis and
oesophageal cancer) and control subjects, but was unable
to demonstrate a signiﬁcant diﬀerence. The hypothesis
of diﬀerential toxicity of alcohol and tobacco warrants
further exploration. But such discrepancies are also found in
epidemiological studies. An Italian study [12] demonstrated
an increased risk of oesophageal cancers among cirrhotic
patients (odds ratio of 2.6), but a Danish cohort study [13]
failed to demonstrate such an association. The proportion
of female patients in our case group (20%) was higher than
in the overall population of patients treated for oesophageal
cancer in our institution (9%). Here again the question
concerns the underlying source of the diﬀerence: genetic
eﬀect, type of alcoholism?
Beyond the fact that surgery was not performed for
any of the cirrhotic patients, it is clear that the proposed
therapeutic options were quite similar for all patients.
Radiochemotherapy, generally with a Herskovic protocol
[6], was proposed for the large majority of patients in
both groups. Toxicity was not signiﬁcantly worse in the
case group, patients in this group even presenting fewer
episodes of mucitis! This diﬀerence cannot be explained by
an excess of mucosal toxicity in our control population since
the proportion was similar to that reported by Herskovic
et al. [6]. It might be explained by the lower 5FU dose
administered in our case group patients starting from the
ﬁrst cycle, in line with the conclusions of Bleiberg et al. [14]
who demonstrated less toxicity (but comparable eﬃcacy) in
patients given palliative treatment using CDDP alone com-
pared with 5FU-CDDP. Despite the initial hypersplenism
subsequent to the portal hypertension, our case group
patients did not present a signiﬁcantly increased rate of
hematological complications. This is probably because these
patients had a peripheral rather than central hematological
disorder. We did not note any renal toxicity, but ﬂuid
infusion did lead to decompensation with edema and ascites
in 5 patients. This suggests that CDDP doses should be
fractionated for this type of patient in order to limit ﬂuid
overloadorthatcarboplatinshouldbeusedinsuchhigh-risk
patients.
Despite the absence of a signiﬁcant diﬀerence between
the groups, there were more deaths in the case group (19%)
than in the control group (6%). Most of the deaths were
related to complications of cirrhosis and occurred in patients
with Child B disease. This very poor tolerance to treatment
is probably suﬃcient to prefer radiation alone for Child B
patients instead of the classical radiochemotherapy protocol.
The proportion of patients who achieved compete remis-
sion at the end of treatment was similar in the two groups,
a result which is coherent with the identical radiation and
chemotherapy doses delivered. The overall and recurrence-
freesurvivalswerealsoequivalentforthetwogroups,aresult
whichiscoherentwiththenaturalhistoryofthetwodiseases:
initial overmortality in cirrhotic patients masked by the
dismalprognosisofoesophagealcancer;absenceofcirrhosis-
related overmortality after chemoradiotherapy since the only
surviving cirrhosis patients were Child A.
5. Conclusion
We found that the proportion of patients with oesophageal
cancer who have cirrhosis is low despite similar favor-
ing factors in our population (population without any
alcohol ﬂushing response) [15]. Patients with oesophageal
cancer and well compensated cirrhosis (Child A) tolerate
radiochemotherapy as well as patients with oesophageal
cancer alone and respond similarly in terms of antitumor
eﬀect and survival. Patients with more severe liver disease
(Child B) develop serious cirrhosis-related complications
contraindicating a classical radiochemotherapy protocol.
Thus for patients with cancer of the oesophagus and
cirrhosis, it would appear advisable to propose a classical
regimen for Child A patients and a less aggressive treatment
(radiotherapy, endoscopic treatment) for Child B patients.
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